Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S286 LDAC in 5 patients, and decitabine (DAC) in 1 patient. The overall composite CR rate (CCR) was 59% (n=10/17), including 1 patient with incomplete counts recovery (CRi). Molecular MRD negativity was achieved in 6/10 complete responders. Reasons for treatment discontinuation were disease progression/refractoriness (n=10), HSCT (n=4), and unrelated liver disease (n=1). Median event-free and overall survival (EFS, OS) for the whole cohort were 11.8 and 11.9 months, respectively. A detrimental impact of FLT3ITD mutation on CR rate, EFS, and OS was highlighted. Treatment was overall well tolerated, myelosuppression being predictably the most common therapy-related adverse event. Keywords: AML, venetoclax, relapsed/refractory AML-288 The Result of Post Chemotherapy Bone Marrow Recovery in Patients With Acute Leukemia and Lymphoid Malignancies Erdenebaatar Elbegjargal MD, MSc1,2, Norov Oyundelger MD, 1, Batsukh Khishigjargal MD, Ph.D1, Sukhbaatar Myadagsuren MD, MSc1, Ayurzana Nansalmaa MD, MSc1, Gonchigdash Chinbat MD1, Boldbaatar Altanshagai MD, MSc1, Davaasambuu Bulgan MD, Ph.D1, Purevsuren Baljinnyam MD, MSc1, Altangerel Otgonbat MD, Ph.D3 1First Central Hospital of Mongolia, Hematology and Bone Marrow Transplantation Center, Ulaanbaatar, Mongolia. 2Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia. 3Lecturer Department of Hematology, School of Medical Sciences, Ulaanbaatar, Mongolia Background: Post-chemotherapy bone marrow recovery with leukemia patients is defined by increasing absolute neutrophil counts and platelet counts in the complete blood count (CBC). Recent studies have shown that IFR, a new routine and more sensitive parameter compared to others, can give the idea of the earliest morphologic change of bone marrow recovery after chemotherapy. During the period of marrow suppression, extensive monitoring of blood counts is required to assess hemopoietic recovery. Purpose: This study aims to evaluate post-chemotherapy and post-stem cell transplantation bone marrow recovery with patients with hematological malignancies by immature reticulocyte fraction and compare results with an absolute neutrophil count. Method and Materials: The study was conducted using an observational crosssectional and prospective cohort study based on clinical cases from January 2022 to February 2023 and involved twenty patients who underwent chemotherapy for acute leukemia and autotransplantation due to lymphoid malignancies. Before and post-chemotherapy, in the CBC, the immature reticulocyte fraction (IRF) was compared with the absolute neutrophil count (ANC) using the “Sysmex XN 2000” analyser to determine the bone marrow recovery. Statistical analysis was performed using the Stata 12.0, and Paired t-test was used. Results: The mean age of the participants was 40±13 years, 10 (50%) patients were male, and 10 (50%) patients were female. Before polychemotherapy, IRF was 14.48±8.6%, ANC 4.4±6.05x109/l; on the first day after polychemotherapy, IRF was 1.78±2.9%, and ANC was 0.92 ±1.73x109/l respectively. The participant’s bone marrow recovery days were calculated as IRF ≥ 5% and ANC ≥1.5×109/L in peripheral blood. The mean bone marrow recovery days were 15.15±3.68 (CI [13.4; 16.8]) for IRF, and 30.45±23.69 for ANC (CI [19.3; 41.5]), P=0.001, showing earlier IRF recovery by an average of 15 days. In 85% of all cases, IRF has indicated the earliest parameter of bone marrow recovery compared to ANC. Conclusions: 1. IRF can serve as an additional reliable parameter in patients who require an assessment of post-chemotherapy bone marrow recovery. 2. IRF can predict bone marrow recovery earlier than ANC count. Keywords: AML, immature reticulocyte fraction, absolute neutrophil count, bone marrow recovery, case AML-298 Acute Promyelocytic Leukemia (APL): The Kuwait Experience Ahmad Alhuraiji MD, Nermin Salem MD, Faran Naim MD, Mohan Ram MD, Anitha Kunhikrishnan MD, Salem Alshemmari MD, Abdulaziz Hamadah MD, Mahmoud Hassaneen MD, Rasha Galal MD, Abdul Rashid Shah MD, FACP, Fatima Khadadah MBBCh, FRCPC, Ramesh Pandita MD Department of Hematology, Kuwait Cancer Control Center, Kuwait Introduction: APL is a highly curable malignancy with a high risk of early morbidity and mortality due to bleeding, differentiation syndrome, and infection. We reviewed the baseline characteristics, clinical course, and treatment outcomes of APL patients in Kuwait. Methods: Between 2010 to April 2023, 56 patients with APL were included. Demographics and baseline hematological parameters were recorded, including hemoglobin, white blood cell (WBC) and platelet count, fibrinogen, and PT/APTT. Symptoms at presentation and the patient’s Sanz risk category were recorded. Treatment regimens and outcomes were also recorded. Results: Median age was 41 years with a male-to-female ratio of 1.41 and a Kuwaiti-to-non-Kuwaiti patient ratio of 0.21. Baseline parameters showed median hemoglobin 81.5g/L (range 29-146), median WBC 4.4x 109/L (range 0.4-83), median platelets 19x 109/L (range 4-148), hypofibrinogenemia in 30.3% (N=17) (median 2.18 g/L, range 1.03-5.8), median prothrombin time 18.9s (range 12.1207), median partial thromboplastin time 28.85s (range 18.571.5). Baseline immunophenotype revealed CD 13 positivity in 94.6%, CD33 positivity in 98.2%, CD34 negativity in 85.7%, and HLADR negativity in 96.4%. All patients (100%) were FISH t (15; 17)-positive, e and 55 (98%) were PML RARA-positive based on RT PCR. Complications at presentation were bleeding in 39 (69.6%), infections in 27(48.2%,) and anemia in 17(30.3%) patients. Per the Pethema risk category, 14 (25%) were high risk, 34 (60.7%) were intermediate risk, and 8 (14.2%) were low risk. Thirty patients (53.5%) received the AIDA treatment protocol, 2 (3.5%) received the ATRA+ATO+IDA protocol, and 22 (39.2%) received ATRA + ATO regimen. Among 54 evaluable patients, fifty-three (98.1%) achieved CR. Complications during induction therapy were febrile neutropenia 27 (48.2%) and differentiation syndrome
RkJQdWJsaXNoZXIy MTk3NTQxMg==